Neurological Adverse Effects after Radiation Therapy for Stage II Seminoma
نویسندگان
چکیده
We report 3 cases of patients with testicular cancer and stage II seminoma who developed neurological symptoms with bilateral leg weakness about 4 to 9 months after radiation therapy (RT). They all received RT to the para-aortic lymph nodes with a total dose of 40 Gy (36 Gy + 4 Gy as a boost against the tumour bed) with a conventional fractionation of 2 Gy/day, 5 days per week. RT was applied as hockey-stick portals, also called L-fields. In 2 cases, the symptoms fully resolved. Therapeutic irradiation can cause significant injury to the peripheral nerves of the lumbosacral plexus and/or to the spinal cord. RT is believed to produce plexus injury by both direct toxic effects and secondary microinfarction of the nerves, but the exact pathophysiology of RT-induced injury is unclear. Since reported studies of radiation-induced neurological adverse effects are limited, it is difficult to estimate their frequency and outcome. The treatment of neurological symptoms due to RT is symptomatic.
منابع مشابه
Cost-effectiveness of posttreatment surveillance after radiation therapy for early stage seminoma.
BACKGROUND This study evaluated the cost-effectiveness of posttreatment surveillance after radiation therapy for early stage seminoma. METHODS From 1988-1995, 47 patients with Stage I, and 11 patients with Stage II seminoma (based on the Royal Marsden staging system) received paraaortic and pelvic lymph node radiation after radical orchiectomy. Patient records were reviewed and patients surve...
متن کاملLong‐term outcomes following post‐operative radiotherapy for Stage I/II testicular seminoma – an Australasian single‐institution experience
INTRODUCTION The aim of the study is to review the long-term oncological outcomes and adverse effects of post-operative radiotherapy (PORT) for Stage I/II seminoma patients in an Australian radiation treatment centre. METHODS This is a retrospective study of 125 patients with Stage I/II seminoma treated with PORT at the Alfred Health Radiation Oncology Service between 1992 and 2013. Patients ...
متن کاملStage I seminoma: adjuvant treatment is effective but is it necessary?
Over the past 40 years, the incidence of testicular cancer has increased in almost all populations worldwide, and it remains the most common solid malignancy in young men between the ages of 20 and 35 years. Primary germ cell tumors are the predominant histological type, with approximately 60% of germ cell tumors being pure seminoma, 30% being nonseminomatous germ cell tumors, and 10% being mix...
متن کاملNeoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma.
BACKGROUND Extended field radiotherapy is a standard of care for low volume stage II testicular seminoma. We hypothesized that neoadjuvant carboplatin might reduce the recurrence risk. PATIENTS AND METHODS In a single-arm study, 51 patients were treated between May 1996 and November 2011 with a single cycle of carboplatin followed by radiotherapy. The radiation field was reduced from an exten...
متن کاملChoosing Treatment for Stage I Seminoma: Who Should Get What?
Lawrentschuk and Fleshner accurately depict the difficulty in choosing among observation, prophylactic radiation, and adjuvant chemotherapy for clinical stage I testicular seminoma. The physican has competing priorities of avoiding unnecessary treatment while minimizing the overall burden of both therapy and surveillance testing. The patient has to contend with defined risks that exist with any...
متن کامل